Pioglitazone
Pioglitazone (Actos), thiazolidinedione PPAR-gamma agonist
Written by Aaron CuhaReviewed Sep 2026
Also known as: Actos, Thiazolidinedione, TZD
An approved diabetes drug with real cardiovascular outcome data in people, and the only compound in the 2026 mouse cohort that shortened female lifespan in the analysis that survived removing an outlier site.
Overview
Pioglitazone is an unusual entry because its human record is strong and its ageing record is negative, and both deserve saying in the same breath.
In people it is an approved insulin sensitiser with a genuine outcome trial behind it, which most things on this site do not have. It also carries well-documented harms: fluid retention, weight gain, heart failure risk and bone fracture risk, particularly in women.
In the mouse lifespan programme it failed, and worse than failed. Among the eleven compounds in the 2026 cohort, pioglitazone was one of two whose negative effect on female lifespan survived the reanalysis that excluded an outlier site with unusually long-lived controls. The coverage document recorded a female median reduction of about 9.4 percent.
Anyone treating a PPAR-gamma agonist as a longevity intervention should read that result first.
Mechanism of action
An agonist at peroxisome proliferator-activated receptor gamma, a nuclear receptor expressed most highly in adipose tissue. Activating it drives differentiation of new small insulin-sensitive adipocytes, redistributes lipid away from liver and muscle, and lowers circulating free fatty acids, which is how it improves whole-body insulin sensitivity. The same receptor activity drives sodium retention in the kidney, which is the mechanism behind the oedema and heart failure risk, and shifts marrow stem cells toward fat rather than bone, which is the plausible route to the fracture signal.
Human evidence
Extensive. Pioglitazone is an approved drug with decades of use, randomised outcome data and a well-characterised harm profile. None of that human evidence concerns ageing or lifespan.
- Approved for type 2 diabetes and reliably improves insulin sensitivity and glycaemic control.
- Carries a boxed warning for congestive heart failure, driven by PPAR-gamma-mediated sodium and fluid retention.
- Weight gain and peripheral oedema are common and expected, not idiosyncratic.
- An increased fracture risk, most clearly in women, is documented and is consistent with the marrow effects of PPAR-gamma agonism.
- It reduces liver fat, which is why it recurs in steatotic liver disease research.
- No human trial has tested it for any ageing endpoint.
What this does not tell you: The human record tells you this drug treats diabetes and carries specific risks. It says nothing about healthspan or lifespan, and the only rigorous lifespan test that exists found no benefit and a female harm signal. Extrapolating from insulin sensitisation to longevity is exactly the inference the mouse data contradicts.
Reading the research record
This compound was one of eleven in the Interventions Testing Program cohort reported in 2026, and none of the eleven significantly increased lifespan in either sex. The cohort is worth understanding as a whole. It deliberately retested astaxanthin, mitoglitazone and meclizine, three compounds the same programme had previously found to extend lifespan, at different doses or starting at later ages. All three showed no benefit the second time. In females, pooling all three sites, astaxanthin, late-start mitoglitazone and pioglitazone were associated with significantly reduced lifespan; site-specific reanalysis found unusually long-lived control females at one site, and excluding it left the negative effect for mitoglitazone and pioglitazone only. The authors' own conclusion is that timing and dosage are critical variables and that single-site or single-cohort findings need cautious interpretation.
Pioglitazone matters more than the other nulls in that cohort because the reasoning behind testing it was good. Insulin sensitivity tracks with longevity across species, caloric restriction improves it, and metformin's ageing case rests partly on it. If improving insulin sensitivity extended life, this drug should have done it. It did not, and in females it went the other way.
The Interventions Testing Program is run by the National Institute on Aging at three independent sites, The Jackson Laboratory, the University of Michigan and the University of Texas Health Science Center at San Antonio. It uses UM-HET3 mice, a genetically heterogeneous four-way cross, so a result cannot be an artefact of one inbred strain. Compounds are fed in the diet, both sexes are tested, cohorts are large enough to detect roughly a 10 percent lifespan change, and results are analysed by log-rank for median survival and by the Wang-Allison test for maximum lifespan. Its nulls are published alongside its positives. That combination of features does not exist anywhere else in ageing research, which is why a null here means considerably more than a null from a single laboratory.
The evidence, charted
Fig. 1 · evidence composition
0of 1 citation (0%) is in people
Every citation cited here is Animal work; no other study type is cited on this page. This count is of our own citation list and understates any literature larger than the sources we cite.
Fig. 2 · evidence over time
Every citation here was published in 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2026
Astaxanthin, meclizine, mitoglitazone, pioglitazone, alpha-ketoglutarate, mifepristone, methotrexate, and atorvastatin-telmisartan do not increase lifespan
Interventions Testing Program, eleven compounds in UM-HET3 mice across three sites. None significantly increased lifespan in male or female mice. In females, pooling all sites, astaxanthin, late-start mitoglitazone and pioglitazone were associated with significantly reduced lifespan. After excluding one site whose control females lived unusually long, the negative effect remained for mitoglitazone and pioglitazone only.
GeroScience
Frequently asked questions
Does pioglitazone extend lifespan?
No. In the only rigorous multi-site mouse lifespan test, it did not increase lifespan in either sex, and in females it was associated with significantly reduced lifespan in the analysis that survived excluding an outlier site. No human lifespan data exists.
Should I take it for insulin resistance if I do not have diabetes?
That is a question for a prescriber, and the relevant facts are that it works on insulin sensitivity, carries a boxed warning for heart failure, causes weight gain and fluid retention, and raises fracture risk in women. The ageing rationale that might have justified accepting those risks is not supported by the lifespan data.
Why does a diabetes drug appear in a longevity database?
Because it was formally tested as a longevity intervention by the National Institute on Aging and failed. A compound tested and found not to work is more informative than one nobody has tested, and almost nowhere publishes that.